Antidepressants suppress neuropathic pain by a peripheral β2-adrenoceptor mediated anti-TNFα mechanism

Neurobiology of Disease

Volumn 60, Issue , 2013, Pages 39-50

  Bohren, Yohann ^a,b   Tessier, Luc Henri ^a   Megat, Salim ^a,b   Petitjean, Hugues ^a,b   Hugel, Sylvain ^a   Daniel, Dorothée ^a   Kremer, Mélanie ^a,b   Fournel, Sylvie ^a,b   Hein, Lutz ^c   Schlichter, Rémy ^a,b   Freund Mercier, Marie José ^a,b   Yalcin, Ipek ^a   Barrot, Michel ^a  

^a CNRS   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Adrenoceptor; Allodynia; Antidepressant; Cytokine; Dorsal root ganglia; Neuropathy; Noradrenergic; Pain; Satellite; TNF

Indexed keywords

ANTIDEPRESSANT AGENT; BETA 2 ADRENERGIC RECEPTOR; ETANERCEPT; INFLIXIMAB; NORADRENALIN; NORTRIPTYLINE; TERBUTALINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VENLAFAXINE;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; EVENING DOSAGE; MALE; MORNING DOSAGE; MOUSE; NEUROPATHIC PAIN; NONHUMAN; NORADRENERGIC SYSTEM; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR UPREGULATION; SATELLITE CELL; SPINAL GANGLION; SYMPATHECTOMY;

ACIDIC RIBOSOMAL PHOSPHOPROTEIN P0; ADRENOCEPTOR; ALLODYNIA; ANTIDEPRESSANT; ARBP; CALCITONIN GENE RELATED PEPTIDE; CGRP; CYTOKINE; DORSAL ROOT GANGLIA; GLUTAMINE SYNTHETASE; GS; IL; INTERLEUKIN; NEUROFILAMENT 200; NEUROPATHIC PAIN GROUP; NEUROPATHY; NF200; NORADRENERGIC; NP; PAIN; SATELLITE; TCA; TH; TNFΑ; TRICYCLIC ANTIDEPRESSANT; TUMOR NECROSIS FACTOR Α; TYROSINE HYDROXYLASE; Β2-ADRENOCEPTOR; Β2-AR;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIDEPRESSIVE AGENTS, TRICYCLIC; GANGLIA, SPINAL; IMMUNOGLOBULIN G; MALE; MICE; MICE, INBRED C57BL; NEURALGIA; NOREPINEPHRINE; NORTRIPTYLINE; PAIN MEASUREMENT; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84883678464     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.08.012     Document Type: Article

References (66)

1. Alba-Delgado C., et al. Chronic pain leads to concomitant noradrenergic impairment and mood disorders. Biol. Psychiatry 2013, 73:54-62.
2. Attal N., et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur. J. Neurol. 2006, 13:1153-1169.
3. Attal N., et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur. J. Neurol. 2010, 17:1113-e88.
4. Attal N., et al. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain 2011, 152:2836-2843.
5. Austin P.J., Moalem-Taylor G. The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J. Neuroimmunol. 2011, 229:26-50.
6. Barrot M. Tests and models of nociception and pain in rodents. Neuroscience 2012, 211:39-50.
7. Barrot M., et al. From antidepressant drugs to beta-mimetics: preclinical insights on potential new treatments for neuropathic pain. Recent Pat. CNS Drug Discov. 2009, 4:182-189.
8. Barrot M., et al. Antidepressant treatment of neuropathic pain: looking for the mechanism. Future Neurol. 2010, 5:247-257.
9. Benbouzid M., et al. Chronic, but not acute, tricyclic antidepressant treatment alleviates neuropathic allodynia after sciatic nerve cuffing in mice. Eur. J. Pain 2008, 12:1008-1017.
10. Benbouzid M., et al. Sciatic nerve cuffing in mice: a model of sustained neuropathic pain. Eur. J. Pain 2008, 12:591-599.
11. Bohren Y., et al. Mu-opioid receptors are not necessary for nortriptyline treatment of neuropathic allodynia. Eur. J. Pain 2010, 14:700-704.
12. Cabal-Hierro L., Lazo P.S. Signal transduction by tumor necrosis factor receptors. Cell. Signal. 2012, 24:1297-1305.
13. Choucair-Jaafar N., et al. Beta2-adrenoceptor agonists alleviate neuropathic allodynia in mice after chronic treatment. Br. J. Pharmacol. 2009, 158:1683-1694.
14. Choucair-Jaafar N., et al. Cardiovascular effects of chronic treatment with a β2-adrenoceptor agonist relieving neuropathic pain in mice. Neuropharmacology 2011, 61:51-60.
15. Chruscinski A.J., et al. Targeted disruption of the beta2 adrenergic receptor gene. J. Biol. Chem. 1999, 274:16694-16700.
16. Cok O.Y., et al. Is there a place for beta-mimetics in clinical management of neuropathic pain? Salbutamol therapy in six cases. Anesthesiology 2010, 112:1276-1279.
17. Dworkin R.H., et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007, 132:237-251.
18. El Mansari M., et al. Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS Neurosci. Ther. 2010, 16:e1-e17.
19. Elenkov I.J., et al. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol. Rev. 2000, 52:595-638.
20. Empl M., et al. TNF-alpha expression in painful and nonpainful neuropathies. Neurology 2001, 56:1371-1377.
21. Hanani M. Satellite glial cells in sensory ganglia: from form to function. Brain Res. Brain Res. Rev. 2005, 48:457-476.
22. Hao S., et al. Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther. 2007, 14:1010-1016.
23. Hetier E., et al. Modulation of interleukin-1 and tumor necrosis factor expression by beta-adrenergic agonists in mouse ameboid microglial cells. Exp. Brain Res. 1991, 86:407-413.
24. Ho C., O'Leary M.E. Single-cell analysis of sodium channel expression in dorsal root ganglion neurons. Mol. Cell. Neurosci. 2010, 46:159-166.
25. Jensen T.S., et al. A new definition of neuropathic pain. Pain 2011, 152:2204-2205.
26. Kaufling J., et al. Pharmacological recruitment of the GABAergic tail of the ventral tegmental area by acute drug exposure. Br. J. Pharmacol. 2010, 161:1677-1691.
27. Korhonen T., et al. The treatment of disc herniation-induced sciatica with infliximab: results of a randomized, controlled, 3-month follow-up study. Spine (Phila Pa 1976) 2005, 30:2724-2728.
28. Krell H.V., et al. Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain. Psychosomatics 2005, 46:379-384.
29. Lee H.L., et al. Temporal expression of cytokines and their receptors mRNAs in a neuropathic pain model. Neuroreport 2004, 15:2807-2811.
30. Leung L., Cahill C.M. TNF-alpha and neuropathic pain-a review. J. Neuroinflammation 2010, 7:27.
31. Lindenlaub T., Sommer C. Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies. Acta Neuropathol. 2003, 105:593-602.
32. MacEwan D.J. TNF receptor subtype signalling: differences and cellular consequences. Cell. Signal. 2002, 14:477-492.
33. Mantyh P.W., et al. Beta 2-adrenergic receptors are expressed by glia in vivo in the normal and injured central nervous system in the rat, rabbit, and human. J. Neurosci. 1995, 15:152-164.
34. Maruo K., et al. Modulation of P2X receptors via adrenergic pathways in rat dorsal root ganglion neurons after sciatic nerve injury. Pain 2006, 120:106-112.
35. McCoy M.K., Tansey M.G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflammation 2008, 5:45.
36. McLachlan E.M., et al. Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature 1993, 363:543-546.
37. Mico J.A., et al. Antidepressants and pain. Trends Pharmacol. Sci. 2006, 27:348-354.
38. Millan M.J. Descending control of pain. Prog. Neurobiol. 2002, 66:355-474.
39. Mosconi T., Kruger L. Fixed-diameter polyethylene cuffs applied to the rat sciatic nerve induce a painful neuropathy: ultrastructural morphometric analysis of axonal alterations. Pain 1996, 64:37-57.
40. Nakamura A., et al. Regulation of tumour necrosis factor and interleukin-6 gene transcription by beta2-adrenoceptor in the rat astrocytes. J. Neuroimmunol. 1998, 88:144-153.
41. Neil A., et al. Effects of guanethidine on sensitization to natural stimuli and self-mutilating behaviour in rats with a peripheral neuropathy. Brain Res. 1991, 565:237-246.
42. Peng X.M., et al. Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury. Ann. Neurol. 2006, 59:843-851.
43. Ramer M.S., Bisby M.A. Normal and injury-induced sympathetic innervation of rat dorsal root ganglia increases with age. J. Comp. Neurol. 1998, 394:38-47.
44. Saarto T., Wiffen P.J. Antidepressants for neuropathic pain. Cochrane Database Syst. Rev. 2007, CD005454.
45. Santello M., Volterra A. TNFalpha in synaptic function: switching gears. Trends Neurosci. 2012, 35:638-647.
46. Scallon B., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther. 2002, 301:418-426.
47. Schmittgen T.D., Zakrajsek B.A. Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. J. Biochem. Biophys. Methods 2000, 46:69-81.
48. Severn A., et al. Regulation of tumor necrosis factor production by adrenaline and beta-adrenergic agonists. J. Immunol. 1992, 148:3441-3445.
49. Sommer C., et al. Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. Brain Res. 2001, 913:86-89.
50. Sommer C., et al. Etanercept reduces hyperalgesia in experimental painful neuropathy. J. Peripher. Nerv. Syst. 2001, 6:67-72.
51. Suzuki T., et al. Antiallodynic and antihyperalgesic effect of milnacipran in mice with spinal nerve ligation. Anesth. Analg. 2008, 106:1309-1315. (table of contents).
52. Szelenyi J., et al. Differential involvement of sympathetic nervous system and immune system in the modulation of TNF-alpha production by alpha2- and beta-adrenoceptors in mice. J. Neuroimmunol. 2000, 103:34-40.
53. Thacker M.A., et al. Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth. Analg. 2007, 105:838-847.
54. Tobinick E., Davoodifar S. Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr. Med. Res. Opin. 2004, 20:1075-1085.
55. Trimmer P.A., et al. Combination of immunocytochemistry and radioligand receptor assay to identify beta-adrenergic receptor subtypes on astroglia in vitro. J. Neurosci. 1984, 4:1598-1606.
56. Uceyler N., et al. Early cytokine expression in mouse sciatic nerve after chronic constriction nerve injury depends on calpain. Brain Behav. Immun. 2007, 21:553-560.
57. Vallejo R., et al. The role of glia and the immune system in the development and maintenance of neuropathic pain. Pain Pract. 2010, 10:167-184.
58. van der Poll T., et al. Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood. Infect. Immun. 1994, 62:2046-2050.
59. von Hehn C.A., et al. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 2012, 73:638-652.
60. Wagner R., Myers R.R. Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. Neuroreport 1996, 7:2897-2901.
61. White F.A., et al. Chemokine signaling and the management of neuropathic pain. Mol. Interv. 2009, 9:188-195.
62. Yalcin I., et al. Beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann. Neurol. 2009, 65:218-225.
63. Yalcin I., et al. Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain. Neurobiol. Dis. 2009, 33:386-394.
64. Yalcin I., et al. Chronic treatment with agonists of beta(2)-adrenergic receptors in neuropathic pain. Exp. Neurol. 2010, 221:115-121.
65. Yoshimura M., Furue H. Mechanisms for the anti-nociceptive actions of the descending noradrenergic and serotonergic systems in the spinal cord. J. Pharmacol. Sci. 2006, 101:107-117.
66. Zhou Z., et al. A novel cell-cell signaling by microglial transmembrane TNFalpha with implications for neuropathic pain. Pain 2010, 151:296-306.